Skip to content

Belite Bio

US · BLTE #1866 by market cap Listed 2022
127.38 -23.64 -15.65%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 129.20 -14.45%
After-hours 127.38 0.00%
Overnight 145.00 -3.99%
193.61127.38127.382026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on BLTE?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -2.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 3.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Return on equity -16.9% Better than 17%
Return on invested capital -18.4% Better than 14%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -20.9% Better than 29%
6-month return -7.2% Better than 44%
12-month return (ex latest month) 24.6% Better than 64%
Distance below 52-week high 36.3% Better than 33%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 50.0x Better than 100%
Debt to assets 0.1% Better than 99%
Interest coverage -38,804.5x Better than 0%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 81.9% Better than 79%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -22.50%
1M -17.53%
3M -21.34%
6M -11.15%
YTD -20.37%
1Y +16.67%
3Y +233.28%

Key statistics

Price & volume

Prev close
151.02
Open
129.00
Day range
120.00 - 135.07
Avg price
129.94
Volume
1.04M
Turnover
134.88M
Amplitude
9.98%
52-week range
115.41 - 200.00

Valuation

P/E
-55.14
P/E (TTM)
-44.85
P/B
6.71
EPS
-2.31
Net profit
-93.82M
Net assets
771.06M

Share structure

Market cap
5.17B
Float cap
2.53B
Shares out
40.61M
Float shares
19.85M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2022-04-29
52-week range 14% of range
115.41 200.00

36.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-12.67M net over the window

Short interest

Shares short
1.38M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Belite Bio (BLTE)?

Belite Bio last traded at 127.38. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Belite Bio's market cap?

About 5.17B.

What is the P/E ratio of Belite Bio?

The trailing twelve-month P/E is -44.85. The Valuation tab shows it against the stock's own five-year range.

Does Belite Bio pay a dividend?

Belite Bio does not currently pay a regular dividend.

Is Belite Bio a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 231.67, which implies 81.9% upside from the current price. This is not investment advice.

What is Belite Bio's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Belite Bio a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Belite Bio discussion 0 comments

Add a comment